New diabetes drug tested in liver health study
NCT ID NCT07540754
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study looks at how the body processes HRS9531 injection in people with mild or moderate liver issues compared to those with healthy livers. Researchers will measure drug levels and check for side effects in 24 participants. The goal is to understand if liver function affects the drug's behavior, not to treat the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- FitBit coaching may help amputees walk more after surgery
- Can shedding pounds reboot the Heart's exercise engine?
- Can AI catch the leading cause of blindness before It's too late?
- Does feeling stigmatized worsen life quality for men with low testosterone?
- Can community hospitals in zambia master severe disease care?
- Can a wearable sensor beat Finger-Prick tests for type 2 diabetes?